Last reviewed · How we verify
5-HTP
5-HTP, marketed by University Hospital, Ghent, is a serotonin precursor used to regulate mood, appetite, and sleep. A key strength is its role as a direct precursor to serotonin, which may offer a natural approach to managing conditions related to serotonin deficiency. The primary risk is the key composition patent expiry in 2028, which could lead to increased competition from generic versions.
At a glance
| Generic name | 5-HTP |
|---|---|
| Also known as | Levotonine |
| Sponsor | University Hospital, Ghent |
| Modality | Small molecule |
| Therapeutic area | Neuroscience |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Pharmacokinetic and Subjective Effects of Heated Tobacco Products (NA)
- Pharmacokinetics and Pharmacodynamics of THS With LEVIA Compared to THS With TEREA and to Cigarettes (NA)
- 5HTP Regulation Of Asthma In Children (PHASE2)
- Tinnitus and Treatment With umPEA-LUT (NA)
- A Replicate Crossover Trial on Nutritional Supplementation in Association Football (Soccer) (NA)
- The Supporting Early Learning Study (NA)
- Effects of 5HTP on the Injured Human Spinal Cord (PHASE2,PHASE3)
- 5-HTP and Creatine for Depression R33 Phase (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- 5-HTP CI brief — competitive landscape report
- 5-HTP updates RSS · CI watch RSS
- University Hospital, Ghent portfolio CI